Literature DB >> 26560085

As-needed intravenous antihypertensive therapy and blood pressure control.

Melissa Lipari1, Lynette R Moser2, Elizabeth A Petrovitch3, Margo Farber4, John M Flack5.   

Abstract

BACKGROUND: Hospitalized patients with elevated blood pressure (BP) in most cases should be treated with intensification of oral regimens, but are often given intravenous (IV) antihypertensives.
OBJECTIVE: To determine frequency of prescribing and administering episodic IV antihypertensives and outcomes.
DESIGN: Retrospective review.
SETTING: Urban academic hospital. PATIENTS: Non-critically ill, hospitalized patients with an IV antihypertensive order for enalaprilat, labetalol, hydralazine, or metoprolol. MEASUREMENTS: We analyzed BP thresholds for ordering and administering IV antihypertensives, the types and frequencies of IV antihypertensives administered, and the effect of IV antihypertensive use on short-term BP and adverse outcomes. The BP change during hospitalization was contrasted in those receiving IV antihypertensives between those who did and did not receive subsequent intensification of chronic oral antihypertensive regimens.
RESULTS: Two hundred forty-six patients had an episodic IV antihypertensive order. One hundred seventy-two patients received 458 doses, with 48% receiving a single dose. Over 98% of episodic IV antihypertensive doses were administered for systolic blood pressure (SBP) <200 mm Hg and 84.5% for SBP <180 mm Hg. Within 6 hours of administration, there was a statistically significant decline in average SBP and diastolic BP in patients receiving IV hydralazine and labetolol. After administration of IV antihypertensives, the oral inpatient medication regimen was adjusted in 52% of patients; these patients had a greater reduction in SBP from admission to discharge than patients with no change to their oral regimens. A total of 32.6% of patients receiving treatment experienced a BP reduction of more than 25% within 6 hours.
CONCLUSIONS: IV antihypertensive drugs are ordered and administered in patients with asymptomatic, uncontrolled BP for levels unassociated with substantive immediate cardiovascular risk, which may cause adverse effects.
© 2015 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26560085     DOI: 10.1002/jhm.2510

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.960


  6 in total

1.  Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients.

Authors:  Michelle F Gaynor; Garth C Wright; Sheryl Vondracek
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-01

2.  Improving the use of intravenous antihypertensive medications in the hospital setting: a quality improvement initiative for patient safety.

Authors:  Jacob Salman; Alicja Salman; Sarwan Kumar; Rudin Gjeka; Vesna Tegeltija; Daymon Peterson; Nour Chams; Ian Ross
Journal:  BMJ Open Qual       Date:  2019-11-27

3.  Severe inpatient hypertension prevalence and blood pressure response to antihypertensive treatment.

Authors:  Lama Ghazi; Fan Li; Xinyuan Chen; Michael Simonov; Yu Yamamoto; Aditya Biswas; Jonathan Hanna; Tayyab Shah; Raymond Townsend; Aldo Peixoto; F Perry Wilson
Journal:  J Clin Hypertens (Greenwich)       Date:  2022-02-17       Impact factor: 2.885

4.  Blood pressure response to commonly administered antihypertensives for severe inpatient hypertension.

Authors:  Lama Ghazi; Fan Li; Xinyuan Chen; Michael Simonov; Yu Yamamoto; Aditya Biswas; Jonathan Hanna; Tayyab Shah; Aldo J Peixoto; F Perry Wilson
Journal:  PLoS One       Date:  2022-04-06       Impact factor: 3.752

5.  Identification of hypertension in hospitalized children prescribed as-needed antihypertensive medication.

Authors:  Kathryn R Kocher; Dmitry Tumin; Amber G Lehmann; Lilliana Michelle Gomez Mendez
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-04       Impact factor: 3.738

6.  Pro Re Nata Antihypertensive Medications and Adverse Outcomes in Hospitalized Patients: A Propensity-Matched Cohort Study.

Authors:  Rajesh Mohandas; Gajapathiraju Chamarthi; Shahab Bozorgmehri; Jeremy Carlson; Tezcan Ozrazgat-Baslanti; Rupam Ruchi; Ashutosh Shukla; Amir Kazory; Azra Bihorac; Muna Canales; Mark S Segal
Journal:  Hypertension       Date:  2021-06-21       Impact factor: 9.897

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.